论文部分内容阅读
Morton等提出受精后,在母亲血清中最早出现的超早孕因子(EPF)以来,在妊娠成立和维持中起作用的免疫应答机理阐明之后,EPF作为受精的标志引人注目。作者用稳定的测定系统,测定受精后早期母体血清中出现的EPF,特别在不妊领域中将EPF测定应用于临床,并对其临床意义进行讨论,结果如下: 1.EPF比β-hCG更早期地被检出,目前一般认为EPF能提供最早妊娠的信息。 2.EPF测定对受精卵,特别是精子的受精能力的判断和研究各因素对受精的影响方面是有用的。在乏精子症,既使通过人工受精(AIH),受精率在10.0～16.7%。 3.通过EPF测定,对受精障碍和着床障碍的鉴别诊断是可能的,能提示存在高发性胚胎丧失。
After the fertilization of Morton et al., The mechanism of immune response that plays a role in the establishment and maintenance of pregnancy since the earliest occurrence of early pregnancy factor (EPF) in maternal serum has been elucidated as a marker of fertilization. The authors used a stable assay system to determine the presence of EPF in early maternal serum after fertilization and, in particular, EPF measurement in the field of non-pregnancy, and its clinical implications were discussed. The results are as follows: 1. EPF was earlier than beta-hCG Was detected, it is generally believed that the EPF can provide the earliest pregnancy information. 2.EPF Determination of fertilized eggs, especially the ability of sperm to judge and determine the factors that affect fertilization is useful. In the case of oligozoospermia, fertilization rates range from 10.0 to 16.7% even with artificial insemination (AIH). By EPF determination, differential diagnosis of impaired and impaired implantation is possible, suggesting the presence of high incidence of embryo loss.